Research programme: cannabinoid-based therapeutics - Axim Biotechnologies

Drug Profile

Research programme: cannabinoid-based therapeutics - Axim Biotechnologies

Alternative Names: Cannabidiol/Gabapentin; Cannbleph™; MedChew-Dronabinol

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axim Biotech
  • Class Antiemetics; Appetite stimulants; Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Restless legs syndrome
  • Research Anorexia; Attention-deficit hyperactivity disorder; Autistic disorder; Conjunctivitis; Infections; Nausea and vomiting; Post-traumatic stress disorders

Most Recent Events

  • 20 Apr 2018 Early research in Infections in USA (unspecified route)
  • 18 Apr 2018 Axim Biotech files for patent protection with European Patent Office for cannabinoid based therapeutics for antibacterial and antifungal activity in Europe
  • 19 Mar 2018 Axim Biotech receives Notice of Allowance for its cannabinoid-based therapeutics for Conjunctivitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top